SCHEMBL525917

SCHEMBL525917

CCOC(=O)c1cnc(Nc2ccc(Cl)cn2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPT P10636 5/20 0.47
ALDH1A1 P00352 4/20 0.47
CDC7 O00311 1/20 0.47
DBF4 Q9UBU7 1/20 0.47
KDR P35968 1/20 0.47
TRPV4 Q9HBA0 1/20 0.47
LCK P06239 4/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035841 0.85 MAPK13 (0.56) RAB9ANPSR1MAPTALDH1A1CDC7
SCHEMBL525976 0.80 KDR (0.58) RAB9ANPSR1MAPTALDH1A1KDR
SCHEMBL27937477 0.80 AURKA (0.44) MAPTALDH1A1CDC7DBF4TRPV4
SCHEMBL21495194 0.79 SIK2 (0.48) CDC7DBF4LCK
SCHEMBL525388 0.79 EGFR (0.58) RAB9ANPSR1MAPTALDH1A1TRPV4
SCHEMBL1541845 0.76 KDR (0.51) CDC7DBF4KDRLCK
SCHEMBL12291072 0.76 CDC7 (0.55) RAB9AMAPTALDH1A1CDC7DBF4
SCHEMBL19390260 0.75 LCK (0.72) LCK
SCHEMBL31661283 0.75 MEN1 (0.67) RAB9ANPSR1MAPTALDH1A1TRPV4
SCHEMBL23334312 0.74 CDC7 (0.54) RAB9AMAPTALDH1A1CDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US disclosed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO disclosed
US-20120029029-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029029-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HSD11B1, HSD11B2, HSD3B1 RAB9A 4547/4885NPSR1 1301/4885MAPT 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.